Inhibition of pancreatic tumor cell growth in culture by p21(WAF1) recombinant adenovirus

Pancreas

Volumn 16, Issue 2, 1998, Pages 107-113

  Joshi, Urwashi S ^a   Dergham, Sanaa T ^a   Chen, Yong Q ^a   Dugan, Michael C ^a   Crissman, John D ^a   Vaitkevicius, Vainutis K ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell growth inhibition; Gene therapy; p21(WAF1); Pancreatic cancer; Recombinant adenovirus

Indexed keywords

BETA GALACTOSIDASE; PROTEIN P21;

ADENOVIRUS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GROWTH INHIBITION; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL CULTURE; TUMOR SUPPRESSOR GENE; VIRUS RECOMBINANT;

EID: 0031932454     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199803000-00001     Document Type: Article

References (36)

1. Parker SL, Tong T, Bolen S. Wingo PA. Cancer Statistics. CA Cancer J Clin 1996;65:5-27.
2. Hruban RH, Yeo CJ, Kern SE. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 1994;8:27-32.
3. Redston MS, Caldas C, Seymour AB, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54:3025-33.
4. Weyrer K, Feichtinger H, Haun M, et al. p53, Ki-ras and DNA ploidy in human pancreatic ductal adenocarcinomas. Lab Invest 1996;74(1):279-89.
5. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 1994;8:27-32.
6. Scuhtte M, da Costa LT, Hahn SA, et al. Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sci USA 1995;92(13):5950-4.
7. Hahn SA, Schutte M, Hoque ATMS, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3.
8. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
9. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-6.
10. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366: 701-4.
11. El-Diery WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
12. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
13. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53 independent pathway. Cancer Res 1994;54:3391-5.
14. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994;369:574-8.
15. Zhang H, Hannon GJ, Casso D, Beach D, eds. p21 is a component of active cell kinases. Cold Spring Harbor Symposia on Quantitative Biology vol. LIX. New York: Howard Hughes National Institute, 1994.
16. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1 to S phase transition. Mol Cell Biol 1995;95:2612-24.
17. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21 C1P1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995;82:675-84.
18. Sheikh MS, Rochefort H, Garcia M. Overexpression of p21 WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene 1995;11: 1899-905.
19. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, el-Houseini ME. Induction of p21(WAF-1/C1P1) during differentiation. Oncogene 1994;9:3389-96.
20. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E, Fisher PB. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21 WAF1/C1P1 expression in the absence of p53. Oncogene 1994;9:3397-406.
21. Halevy O, Novitch BG, Spicer DB, et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995;267:1018-24.
22. Parker SB, Eichele G, Zhang P, et al. p53 independent expression of p21 Cip1 in muscle and other terminally differentiating cells. Science 1995;267:1024-7.
23. Chen YQ, Cipriano SC, Sarkar FH, Ware JL, Arenkiel JM. P53-independent induction of p21(WAF1) pathway is preserved during tumor progression. Int J Oncol 1995;7:889-93.
24. Harris MP, Sutjpto S, Wills KN, et al. Adenovirus mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther 1996;3(2):121-30.
25. Liu TJ, Zhang WW, Talor DL, Roth JA, Goepfert H, Clayman GL. Growth suppression of human head and neck cancer cells by the introduction of a wild type p53 gene via a recombinant adenovirus. Cancer Res 1994;54:3662-7.
26. Liu TS, El-naggar AK, McDonnell TJ, et al. Apoptosis induction mediated by wild type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 1995;55(14): 3117-22.
27. Perez-Cruet MJ, Trask TW, Chen SH, et al. Adenovirus mediated gene therapy of experimental gliomas. J Neurosci Res 1994;39(4): 506-11.
28. Xu HJ, Zhou Y, Seigne J, et al. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Can Res 1996;56: 2245-9.
29. O'Malley BW Jr, Chen SH, Schwartz MR, Woo SL. Adenovirus mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res 1995;55(5):1080-5.
30. Hung MC, Matin A, Zhang Y, Xing X, Sorgi F, Haung L. HER-2/neu targeting gene therapy - a review. Gene 1995;159(1):65-71.
31. Zhang Y, Yu D, Xia W, Hung MC. HER-2/neu targeting cancer therapy via adenovirus mediated E1A delivery in an animal model. Oncogene 1995;10(10):1947-54.
32. Yang ZY, Perkins ND, Ohno T, Nabel EG, Nabel GJ. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nature Med 1995;1(10):1052-6.
33. Eastham JA, Hall SJ, Sehgal I, et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995;55(22): 5151-5.
34. Fotedar R, Fitzgerald P, Rousselle T, et al. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity. Oncogene 1996;12:2155-64.
35. WAF1 expression is related to early stage and increased survival with conventional therapies in pancreatic adenocarcinoma. Mod Pathol 1997; 10:144A.
36. Aoki K, Yoshida T, Sugimura T, Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995;55:3810-6.